Curis | CRIS - Selling And Administration Expenses


Curis reported $2.96M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 447K 138K Mar/2026
Amgen USD 1.72B 134M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
Bayer EUR 3.96B 267M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
CSL USD 1.23B 498M Dec/2025
Curis USD 2.96M 1.62M Mar/2026
Eli Lilly USD 3.43B 496M Jun/2026
Exelixis USD 147.63M 8.03M Jun/2026
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Incyte USD 351.73M 23.64M Jun/2026
Merck USD 2.89B 219M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.63B 307M Jun/2026
Takeda JPY 286.51B 5.48B Jun/2026
TG Therapeutics USD 62.32M 10.82M Jun/2026
Verastem USD 22.3M 2.14M Mar/2026